HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way.
You can best understand what a HER2-mutated NSCLC diagnosis means by breaking down the terms:
HER2-mutated means there is a permanent DNA change in each affected lung cancer cell. This mutation affects the gene that codes for human epidermal growth factor receptor 2 (HER2). HER2 is on most of your cells and tells them when to grow and divide. In these lung cancer cells, the HER2 mutation keeps it stuck in the "on" position, and the cancer cells reproduce unchecked.
Non-small-cell lung cancer is one of the two main types of lung cancer. In comparison to small-cell lung cancer, NSCLC cells are larger and tend to grow more slowly. NSCLC is the most common form of lung cancer, but the HER2 mutation is rare. Only 2% to 4% of all people with NSCLC have this specific mutation.
HER2-Mutated NSCLC Types
HER2-Mutated NSCLC Causes
Researchers have learned a great deal about HER2-mutated NSCLC in recent years but are still working to fully understand how and why these mutations happen.
HER2-Mutated NSCLC Symptoms
The symptoms of HER2-mutated NSCLC are similar to those of other lung cancers:
- A cough that does not go away or worsens over time
- Shortness of breath (feeling out of breath)
- Chest pain or discomfort
- Fatigue (feeling very tired) and weakness
- Unexplained weight loss
- Coughing up blood
If your cancer spreads (metastasizes), you might see symptoms show up in other parts of your body. For example, you may have:
- Bone pain
- Headache (if it spreads to the brain)
- Swelling in lymph nodes
Your symptoms may vary, depending on how early you get a diagnosis and how much your cancer has spread. For some people, symptoms start slowly and mildly and worsen over months. For others, the disease may already be advanced by the time symptoms are obvious.
Studies show that many people with NSCLC of any type are at advanced stages of the disease (stage IV) when they get a diagnosis.
HER2-Mutated NSCLC Diagnosis
Because this form of lung cancer is rare, you often need specialized tests to get an accurate diagnosis. Your doctor first confirms you have lung cancer and then identifies whether it carries a HER2 mutation. Not all doctors or hospitals automatically test for HER2, which means you may need to ask for comprehensive genetic testing.
Testing for HER2-mutated status in NSCLC involves a series of steps:
- Medical history and physical exam. First, your doctor will ask about symptoms, your health history, and risk factors (like smoking). They'll also do a physical exam, looking for signs of cancer.
- Imaging. Your doctor will give you a chest X-ray or CT scan, often as one of the first tests. These images help them see if you have masses or abnormalities in your lungs. If your doctor sees abnormal spots in your lungs, they may order more imaging with a positron emission tomography (PET) or magnetic resonance imaging (MRI) scan to see whether the cancer has spread.
- Biopsy. Doctors usually need a sample of lung tissue to be sure what you have is NSCLC and to also figure out the subtype. The type of biopsy you have (needle, bronchoscopy, or surgery) depends on where your tumor is.
- Molecular testing (genetic testing). Once your doctor confirms you have cancer, they may also test the biopsy tissue for specific genetic changes including HER2 mutations, amplification, or overexpression. They often use next-generation sequencing (NGS), which looks at many genes at once.
- Other tests. Doctors use bloodwork to check your overall health and organ function. If your cancer has spread, your doctor may also biopsy other sites, such as your lymph nodes or brain, to help guide your treatment.
Because HER2-mutated lung cancer is rare, and symptoms overlap with those of other conditions, some doctors may not order genetic testing right away. So doctors can sometimes delay or miss the diagnosis.
Finding Expert Care
Because HER2-mutated NSCLC is uncommon, many community hospitals may not have specialists who treat it often. Finding a cancer center with expertise in precision medicine can improve your treatment choices and access to clinical trials.
To find doctors who have experience with HER2-mutated NSCLC:
- Look for cancer centers known for lung cancer and precision oncology. Major academic hospitals often have molecular tumor boards.
- Use advocacy group directories and rare-disease networks to find doctors with expertise.
- Ask your oncologist for a referral to a thoracic oncology specialist.
- Consider out-of-state care or telemedicine.
- Check for clinical trials at research hospitals or via trial registries.
HER2-Mutated NSCLC Treatment
Doctors now have several treatments that specifically target HER2-mutated NSCLC. These medicines work differently from regular chemotherapy because they go after cancer cells that have certain changes in the HER2 gene.
The best treatment option depends on the type of HER2 mutation you have and what treatments you've already tried.
FDA-approved targeted therapies
As of 2026, the FDA has approved three drugs to treat HER2-mutated NSCLC, with updated indications reflecting new approvals.
Trastuzumab deruxtecan (Enhertu). Enhertu is one of the most commonly used medicines for HER2-mutated NSCLC. You get it through an IV. It's a type of drug called an antibody conjugate. It combines an antibody that finds HER2-positive cancer cells with a chemotherapy drug that kills them. The FDA approved Enhertu for people with metastatic or NSCLC that can't be removed with surgery, who have HER2 mutations, and have already been treated with at least one other cancer therapy. In studies, many people saw their tumors shrink while on this drug.
Sevabertinib (Hyrnuo) and zongertinib (Hernexeos) are newer FDA-approved drugs you take by mouth. They are tyrosine kinase inhibitors (TKIs), which means they block HER2 from sending signals that help cancer cells grow. Zongertinib is approved for adults with non-squamous NSCLC that is metastatic or cannot be removed by surgery that has a HER2 tyrosine kinase domain (TKD) mutation. Both drugs are approved as first-line treatments, meaning eligible patients may receive either one without having tried another systemic treatment first. Zongertinib received its first-line FDA approval in February 2026, followed by sevabertinib's accelerated first-line approval in September 2026.
Other therapies
Doctors also use traditional therapies to help kill cancer cells, such as:
- Radiation therapy, which uses high-powered rays to kill cancer cells
- Immunotherapy, which activates your body's immune system to specifically kill cancer cells. Doctors usually recommended it for late-stage NSCLC.
- Chemotherapy, which kills any fast-growing cells in your body
- Combined therapy, which uses chemotherapy and immunotherapy together. This can sometimes be more effective than using either one alone.
Your doctor may also suggest clinical trials. If you qualify for a clinical trial, you can get access to new medications or therapies that could effectively treat your cancer.
HER2-Mutated NSCLC Complications
As with many other serious illnesses, HER2-mutated NSCLC can lead to complications caused by the cancer itself, the side effects of treatment, or both. Understanding what may happen can help you prepare and plan.
Some possible complications include:
- Side effects of treatment, including interstitial lung disease (ILD)
- Disease spread (metastasis) to the brain, liver, or bones
- Treatment resistance over time
- Reduced lung function
Taking Care of Yourself
Medical treatment is only one part of living with cancer. Organizing information, managing side effects, and maintaining strength and well-being can help you stay active and involved in your care.
To care for symptoms or side effects of treatment, you can try:
- Medications to treat pain, nausea, fatigue, or other symptoms
- Pulmonary rehab or physical therapy
- Care from a nutritionist
- Deep breathing exercises
- Complementary medicine techniques such as acupuncture
To better care for your whole well-being, practice healthy self-care:
- Move your body intentionally and regularly, whether with walks, yoga, stretching, or other forms of physical activity.
- Eat nutritious foods that nourish your body.
- Follow your treatment schedule and see your doctor regularly.
How Your HER2-mutated NSCLC Might Change Over Time
HER2-mutated NSCLC may respond well to treatment at first, then that may change. You may need new treatments or adjustments in your care.
Some people have long stretches of time when their disease is stable and things stay the same. If your cancer begins to grow again, that's called progression. Your cancer may appear in other parts of your body, a spreading that's called metastasis.
If your cancer responds particularly well to your treatment, you may go into remission. That means the signs and symptoms of your cancer have decreased or disappeared.
Getting Support
Many organizations, patient networks, and financial resources exist to help you and your loved ones.
Tap into patient-focused groups that offer connection, information, and advocacy, such as:
Social media is another way to connect with people living with HER2-mutated NSCLC. You can find others who share your experience and feel less alone.
Caring for Your Emotional Health
Living with cancer affects more than the body. Stress, fear, and uncertainty are common, especially with a rare diagnosis. Emotional support can improve well-being and help people stay engaged in their treatment.
Here are ways to care for your emotional health:
- Spend time with friends and loved ones for support and connection.
- Talk to a licensed counselor or therapist for professional mental health help.
- Use mindfulness, meditation, and journaling to sit with your feelings and ground yourself.
- Search out support groups to help reduce feelings of isolation.
Information for Caregivers
Caregivers play a critical support role both practically and emotionally. But caregiving can also be overwhelming, and caregivers need support, information, and rest as well.
If you care for someone with HER2-mutated NSCLC, your role is vital. Here are ways to care well for your loved one and care for yourself, too.
- Learn as much as you can about HER2-mutated NSCLC and its treatments.
- Go to visits when you can and ask questions.
- Create a system to keep up with appointments, medications, and test results.
- Listen and encourage open conversation.
- Take care of yourself by taking intentional breaks, eating well, and exercising.
- Join caregiver support groups.
- Ask for help when you need it.
Takeaways
HER2-mutated NSCLC is a rare lung cancer subtype that requires molecular testing for a diagnosis. The HER2 mutation makes cancer grow uncontrolled. Treatments now include surgery, targeted therapies, immunotherapy, chemotherapy, and clinical trials. Expert care and advocacy are important. Support networks can make a significant difference.
HER2-Mutated NSCLC FAQs
How common is HER2-mutated NSCLC?
HER2 mutations are rare, happening in about 2% to 4% of all NSCLC cases.
Who is more likely to have HER2-mutated lung cancer?
Most people with this subtype of cancer have adenocarcinoma, are younger, and more often are women. Many have never smoked.
Are there FDA-approved treatments for HER2-mutated NSCLC?
As of 2026, there are three targeted therapies approved for HER2-mutated NSCLC: the kinase inhibitors sevabertinib (Hyrnuo) and zongertinib (Hernexeos), and trastuzumab deruxtecan (Enhertu), an antibody-drug conjugate. Sevabertinib (Hyrnuo) is now approved as a first-line option for eligible patients.
What are the side effects of targeted therapy?
They vary by drug. For example, trastuzumab deruxtecan can cause lung inflammation (interstitial lung disease). Side effects may also include low blood counts, fatigue, and nausea.
How do I find a doctor who treats HER2 lung cancer?
Ask for a referral to a thoracic oncologist or a molecular tumor board. Use lung cancer advocacy groups (like LUNGevity) to find expert centers.
